Logo image of SEQUA.BR

SEQUANA MEDICAL NV (SEQUA.BR) Stock Fundamental Analysis

EBR:SEQUA - Euronext Brussels - BE0974340722 - Common Stock - Currency: EUR

0.998  -0.03 (-3.11%)

Fundamental Rating

1

Taking everything into account, SEQUA scores 1 out of 10 in our fundamental rating. SEQUA was compared to 58 industry peers in the Health Care Equipment & Supplies industry. SEQUA has a bad profitability rating. Also its financial health evaluation is rather negative. SEQUA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SEQUA had negative earnings in the past year.
In the past year SEQUA has reported a negative cash flow from operations.
In the past 5 years SEQUA always reported negative net income.
In the past 5 years SEQUA always reported negative operating cash flow.
SEQUA.BR Yearly Net Income VS EBIT VS OCF VS FCFSEQUA.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

The Return On Assets of SEQUA (-251.92%) is worse than 91.38% of its industry peers.
Industry RankSector Rank
ROA -251.92%
ROE N/A
ROIC N/A
ROA(3y)-296.55%
ROA(5y)-236.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SEQUA.BR Yearly ROA, ROE, ROICSEQUA.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

1.3 Margins

SEQUA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SEQUA.BR Yearly Profit, Operating, Gross MarginsSEQUA.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

0

2. Health

2.1 Basic Checks

SEQUA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SEQUA has more shares outstanding
Compared to 5 years ago, SEQUA has more shares outstanding
SEQUA has a worse debt/assets ratio than last year.
SEQUA.BR Yearly Shares OutstandingSEQUA.BR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
SEQUA.BR Yearly Total Debt VS Total AssetsSEQUA.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -35.65, we must say that SEQUA is in the distress zone and has some risk of bankruptcy.
SEQUA has a worse Altman-Z score (-35.65) than 87.93% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -35.65
ROIC/WACCN/A
WACC5.48%
SEQUA.BR Yearly LT Debt VS Equity VS FCFSEQUA.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M -30M -40M

2.3 Liquidity

SEQUA has a Current Ratio of 0.41. This is a bad value and indicates that SEQUA is not financially healthy enough and could expect problems in meeting its short term obligations.
SEQUA has a Current ratio of 0.41. This is amonst the worse of the industry: SEQUA underperforms 89.66% of its industry peers.
A Quick Ratio of 0.29 indicates that SEQUA may have some problems paying its short term obligations.
The Quick ratio of SEQUA (0.29) is worse than 89.66% of its industry peers.
Industry RankSector Rank
Current Ratio 0.41
Quick Ratio 0.29
SEQUA.BR Yearly Current Assets VS Current LiabilitesSEQUA.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 13.49% over the past year.
SEQUA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -85.19%.
SEQUA shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -35.78% yearly.
EPS 1Y (TTM)13.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-17.48%
Revenue 1Y (TTM)-85.19%
Revenue growth 3Y-34.11%
Revenue growth 5Y-35.78%
Sales Q2Q%-100%

3.2 Future

SEQUA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.29% yearly.
Based on estimates for the next years, SEQUA will show a very strong growth in Revenue. The Revenue will grow by 666.97% on average per year.
EPS Next Y47.62%
EPS Next 2Y14.29%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year733.33%
Revenue Next 2Y666.97%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SEQUA.BR Yearly Revenue VS EstimatesSEQUA.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M
SEQUA.BR Yearly EPS VS EstimatesSEQUA.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SEQUA. In the last year negative earnings were reported.
Also next year SEQUA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SEQUA.BR Price Earnings VS Forward Price EarningsSEQUA.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SEQUA.BR Per share dataSEQUA.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as SEQUA's earnings are expected to grow with 14.29% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.29%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SEQUA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SEQUANA MEDICAL NV

EBR:SEQUA (5/29/2025, 7:00:00 PM)

0.998

-0.03 (-3.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-03 2025-04-03/amc
Earnings (Next)N/A N/A
Inst Owners49.55%
Inst Owner ChangeN/A
Ins Owners3.45%
Ins Owner ChangeN/A
Market Cap54.56M
Analysts83.64
Price Target4.05 (305.81%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-20.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)15.38%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-92.3%
Revenue NY rev (3m)-92.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 125.86
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.05
EYN/A
EPS(NY)-0.26
Fwd EYN/A
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.46
OCFYN/A
SpS0.01
BVpS-0.36
TBVpS-0.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -251.92%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-296.55%
ROA(5y)-236.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 100.03%
Cap/Sales 151.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.41
Quick Ratio 0.29
Altman-Z -35.65
F-Score3
WACC5.48%
ROIC/WACCN/A
Cap/Depr(3y)113.39%
Cap/Depr(5y)92.99%
Cap/Sales(3y)87.59%
Cap/Sales(5y)73.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-17.48%
EPS Next Y47.62%
EPS Next 2Y14.29%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-85.19%
Revenue growth 3Y-34.11%
Revenue growth 5Y-35.78%
Sales Q2Q%-100%
Revenue Next Year733.33%
Revenue Next 2Y666.97%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y23.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.97%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y15.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y16.99%
OCF growth 3YN/A
OCF growth 5YN/A